214 related articles for article (PubMed ID: 17157366)
1. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
4. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Markman M; Zanotti K; Peterson G; Kulp B; Webster K; Belinson J
J Clin Oncol; 2003 Dec; 21(24):4611-4. PubMed ID: 14673050
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
Sendo T; Sakai N; Itoh Y; Ikesue H; Kobayashi H; Hirakawa T; Nakano H; Oishi R
Cancer Chemother Pharmacol; 2005 Jul; 56(1):91-6. PubMed ID: 15791461
[TBL] [Abstract][Full Text] [Related]
8. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
9. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
12. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
13. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
15. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
[TBL] [Abstract][Full Text] [Related]
16. A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms.
Piovano E; Pivetta E; Modaffari P; Martra F; Baima Poma C; Perotto S; Tripodi E; Zanfagnin V; Zola P; Ferrero A
Gynecol Obstet Invest; 2012; 74(1):21-7. PubMed ID: 22652565
[TBL] [Abstract][Full Text] [Related]
17. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
18. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Jerzak KJ; Deghan Manshadi S; Ng P; Maganti M; McCuaig JM; Bulter M; Oza A; Mackay HJ
J Oncol Pharm Pract; 2018 Mar; 24(2):83-90. PubMed ID: 27856924
[TBL] [Abstract][Full Text] [Related]
19. Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.
McAlpine JN; Kelly MG; O'malley DM; Azodi M; Coombe K; Schwartz PE; Rutherford TJ
Gynecol Oncol; 2006 Oct; 103(1):288-92. PubMed ID: 16647749
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study.
Koul A; Forsland EL; Bjurberg M
Gynecol Oncol; 2018 Feb; 148(2):363-367. PubMed ID: 29208369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
